A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
In brief
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
Key facts
- Study ID
- NCT04503265
- Run by
- AtlasMedx, Incorporated
- People needed
- 122
- Starts
- 2020-08-12
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2025-05-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology — Los Angeles, California, United States (enrolling)
- Johns Hopkins — Baltimore, Maryland, United States (enrolling)
- SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.